RIA Advisory Group’s Regeneron Pharmaceuticals REGN Stock Holding History

RIA Advisory Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-524	Closed	-$431K	–	131
2023 Q1	$431K	Sell	524 -18	-3%	-$13.6K	0.2%	72
2022 Q4	$391K	Buy	+542	New	+$400K	0.23%	66

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RIA Advisory Group's REGN Position: Q2 2023 in Review

RIA Advisory Group sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 524 shares — an estimated $431K sold.

RIA Advisory Group first reported a position in REGN in Q4 2022 and held it in 2 quarters. The position peaked at $431K in Q1 2023. 1,165 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

RIA Advisory Group reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
RIA Advisory Group sold 524 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $431K.
RIA Advisory Group first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 2 quarters.
RIA Advisory Group's Regeneron Pharmaceuticals position peaked at $431K in Q1 2023.
1,165 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on RIA Advisory Group's 13F filing for Q2 2023, filed 25 Jul 2023.